Trevor L. Schell
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Trevor L. Schell has a total of 46 co-authors. Here are the top co-authors by number of shared publications:
- Freddy Caldera
Division of Gastroenterology and Hepatology, Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, USA
5 shared publications Ian Grimes
Department of Medicine, Division of Gastroenterology & Hepatology, University of Wisconsin School of Medicine & Public Health , Madison, WI , USA
3 shared publicationsArnold Wald
Department of Medicine, Division of Gastroenterology & Hepatology, University of Wisconsin School of Medicine & Public Health , Madison, WI , USA
2 shared publicationsChristine E. McInnis
Department of Chemistry, University of Wisconsin–Madison, 1101 University Avenue, Madison, WI 53706-1322, USA
2 shared publicationsFrancis A Farraye
Mayo Clinic, Division of Gastroenterology & Hepatology, Inflammatory Bowel Disease Center , Jacksonville, FL
2 shared publicationsHiep S Phan
Department of Medicine, University of Wisconsin School of Medicine & Public Health , Madison, WI , USA
2 shared publications
Latest Publications
- 16 December 2025
- Published by Springer Nature in Journal of General Internal Medicine
- Vol. 41 (7) , 2014-2016
Incarcerated Patients Undergoing Colonoscopy are at Increased Risk of Inadequate Bowel Preparation
- 16 December 2025
- Published by Springer Nature in Journal of General Internal Medicine
- Vol. 41 (7) , 2014-2016
Incarcerated Patients Undergoing Colonoscopy are at Increased Risk of Inadequate Bowel Preparation
- 7 March 2025
- Published by Oxford University Press (OUP) in Inflammatory Bowel Diseases
- Vol. 31 (6) , 1754-1755
Optimizing Hepatitis B Vaccination Strategies for Patients With Inflammatory Bowel Disease
- 7 March 2025
- Published by Oxford University Press (OUP) in Inflammatory Bowel Diseases
- Vol. 31 (6) , 1754-1755
Optimizing Hepatitis B Vaccination Strategies for Patients With Inflammatory Bowel Disease
- 20 September 2024
- Published by Oxford University Press (OUP) in Inflammatory Bowel Diseases
- Vol. 31 (7) , 1789-1796
Safety of Rotavirus Vaccination in Infants That Were Exposed to Biologics In Utero: A Systematic Review
Background: In infants that were exposed to biologics in utero, gastroenterology societal guidelines have either recommended against administration of the live rotavirus vaccine until 6-12 months of age or until serum biologic levels are undetectable. We performed a systematic review to evaluate the safety of rotavirus vaccination in biologic-exposed infants. Methods: EMBASE, PubMed, Scopus, and Cochrane databases were searched from 2006 to 2024 for original data reporting on the safety of rotavirus vaccination in infants that were exposed to anti-tumor necrosis factors (TNFs) (ie, infliximab, adalimumab, golimumab, certolizumab) and non-TNF biologics (ie, vedolizumab, ustekinumab, rizankizumab, mirikizumab) in utero. Results: A database search yielded 7185 screening results of which 10 studies met inclusion criteria. There were over 300 instances of rotavirus vaccination in biologic-exposed infants (n = 162 exposed to anti-TNFs, n = 142 exposed to non-TNF biologics). Biologic-exposed infants were not at an increased risk of severe adverse events or adverse events of any severity related to rotavirus vaccination. Conclusions: Administration of the live rotavirus vaccine appears to be safe in biologic-exposed infants. As such, with careful examination of the risks and benefits, there may be a role for rotavirus vaccination in this population.
- 20 September 2024
- Published by Oxford University Press (OUP) in Inflammatory Bowel Diseases
- Vol. 31 (7) , 1789-1796
Safety of Rotavirus Vaccination in Infants That Were Exposed to Biologics In Utero: A Systematic Review
Background: In infants that were exposed to biologics in utero, gastroenterology societal guidelines have either recommended against administration of the live rotavirus vaccine until 6-12 months of age or until serum biologic levels are undetectable. We performed a systematic review to evaluate the safety of rotavirus vaccination in biologic-exposed infants. Methods: EMBASE, PubMed, Scopus, and Cochrane databases were searched from 2006 to 2024 for original data reporting on the safety of rotavirus vaccination in infants that were exposed to anti-tumor necrosis factors (TNFs) (ie, infliximab, adalimumab, golimumab, certolizumab) and non-TNF biologics (ie, vedolizumab, ustekinumab, rizankizumab, mirikizumab) in utero. Results: A database search yielded 7185 screening results of which 10 studies met inclusion criteria. There were over 300 instances of rotavirus vaccination in biologic-exposed infants (n = 162 exposed to anti-TNFs, n = 142 exposed to non-TNF biologics). Biologic-exposed infants were not at an increased risk of severe adverse events or adverse events of any severity related to rotavirus vaccination. Conclusions: Administration of the live rotavirus vaccine appears to be safe in biologic-exposed infants. As such, with careful examination of the risks and benefits, there may be a role for rotavirus vaccination in this population.
- Open Access
- 6 October 2022
- Published by Wolters Kluwer Health in ACG Case Reports Journal
- Vol. 9 (10) , e00864
Fistulizing Cystic Artery Pseudoaneurysm Masquerading as a Bleeding Submucosal Duodenal Lesion
- 6 October 2022
- Published by Wolters Kluwer Health in ACG Case Reports Journal
- Vol. 9 (10) , e00864
Open AccessFistulizing Cystic Artery Pseudoaneurysm Masquerading as a Bleeding Submucosal Duodenal Lesion
- Open Access
- 9 April 2022
- Published by Oxford University Press (OUP) in Inflammatory Bowel Diseases
- Vol. 28 (11) , 1781-1786
Humoral Immunogenicity of 3 COVID-19 Messenger RNA Vaccine Doses in Patients With Inflammatory Bowel Disease
Lay Summary: Herein, we evaluated the humoral immunogenicity of a third coronavirus disease 2019 messenger RNA vaccine dose in patients with inflammatory bowel diseases. All patients displayed a humoral immune response, and median antibody concentrations were higher after the third dose than after completion of the 2-dose series.
- 9 April 2022
- Published by Oxford University Press (OUP) in Inflammatory Bowel Diseases
- Vol. 28 (11) , 1781-1786
Open AccessHumoral Immunogenicity of 3 COVID-19 Messenger RNA Vaccine Doses in Patients With Inflammatory Bowel Disease
Lay Summary: Herein, we evaluated the humoral immunogenicity of a third coronavirus disease 2019 messenger RNA vaccine dose in patients with inflammatory bowel diseases. All patients displayed a humoral immune response, and median antibody concentrations were higher after the third dose than after completion of the 2-dose series.
- Open Access
- 1 April 2022
- Published by Wolters Kluwer Health in ACG Case Reports Journal
- Vol. 9 (4) , e00759
Dysphagia and Odynophagia in a Cardiac Transplant Patient: A Case of Mycophenolic Acid–Induced Esophagitis and Esophageal Stricture
Mycophenolic acid (MPA) is associated with many gastrointestinal (GI) side effects that vary in severity and location. Upper GI effects have previously been attributed to topical mucosal irritation similar to nonsteroidal anti-inflammatory drug pathology. We describe a case of severe MPA-induced esophagitis complicated by esophageal stricture in a patient receiving multiple formulations of MPA, including oral enteric-coated mycophenolate sodium and mycophenolate mofetil administered both intravenous and by J-tube. Endoscopy revealed complete resolution of esophagitis following discontinuation of all MPA formulations, demonstrating that upper GI toxicity may occur because of local and systemic effects.
- 1 April 2022
- Published by Wolters Kluwer Health in ACG Case Reports Journal
- Vol. 9 (4) , e00759
Open AccessDysphagia and Odynophagia in a Cardiac Transplant Patient: A Case of Mycophenolic Acid–Induced Esophagitis and Esophageal Stricture
Mycophenolic acid (MPA) is associated with many gastrointestinal (GI) side effects that vary in severity and location. Upper GI effects have previously been attributed to topical mucosal irritation similar to nonsteroidal anti-inflammatory drug pathology. We describe a case of severe MPA-induced esophagitis complicated by esophageal stricture in a patient receiving multiple formulations of MPA, including oral enteric-coated mycophenolate sodium and mycophenolate mofetil administered both intravenous and by J-tube. Endoscopy revealed complete resolution of esophagitis following discontinuation of all MPA formulations, demonstrating that upper GI toxicity may occur because of local and systemic effects.
- Open Access
Humoral Immunogenicity of Three COVID-19 mRNA Vaccine Doses in Patients with Inflammatory Bowel Disease
Summary: Herein, we evaluated the humoral immunogenicity of a third COVID-19 mRNA vaccine dose in patients with IBD. All patients were seropositive and had higher antibody concentrations after the third dose than after completion of the two-dose primary series.
Open AccessHumoral Immunogenicity of Three COVID-19 mRNA Vaccine Doses in Patients with Inflammatory Bowel Disease
Summary: Herein, we evaluated the humoral immunogenicity of a third COVID-19 mRNA vaccine dose in patients with IBD. All patients were seropositive and had higher antibody concentrations after the third dose than after completion of the two-dose primary series.
- 9 December 2021
- Published by Elsevier in Clinical Gastroenterology and Hepatology
- Vol. 20 (7) , 1606-1608.e2
High But Inequitable COVID-19 Vaccine Uptake Among Patients with Inflammatory Bowel Disease
- 9 December 2021
- Published by Elsevier in Clinical Gastroenterology and Hepatology
- Vol. 20 (7) , 1606-1608.e2
High But Inequitable COVID-19 Vaccine Uptake Among Patients with Inflammatory Bowel Disease
- 23 February 2021
- Published by Springer Nature in Archives of Osteoporosis
- Vol. 16 (1) , 1-12
Opportunistic use of dual-energy X-ray absorptiometry to evaluate lumbar scoliosis
Summary Low bone mineral density is associated with spinal deformity. Dual-energy X-ray absorptiometry (DXA), a modality that assesses bone density, portends a theoretical means to also assess spinal deformity. We found that DXA can reliably assess spine alignment. DXA may permit surveillance of spine alignment, i.e., scoliosis in the clinical setting. Purpose Osteoporosis and scoliosis are interrelated disease processes. Dual-energy X-ray absorptiometry (DXA), used to assess bone density, can also be used to evaluate spinal deformity since it captures a posteroanterior (PA) image of the lumbar spine. We assessed the use of DXA to evaluate lumbar spine alignment. Methods A lumbar spine DXA phantom was used to assess the effects of axial and sagittal plane rotation on lumbar bone mineral content (BMC), density (BMD), and L1–L4 Cobb angle measurements. Using two subject cohorts, intra- and inter-observer reliability and validity of using DXA for L1–L4 Cobb angle measurements in the coronal and sagittal planes were assessed. Results Axial and sagittal plane rotation greater than 15° and 10°, respectively, significantly reduced measured BMD and BMC; there was minimal effect on Cobb angle measurement reliability. In human subjects, excellent intra- and inter-observer reliability was observed using lumbar PA DXA images for Cobb angle measurements. Agreement between Cobb angles derived from lumbar PA DXA images and AP lumbar radiographs ranged from good to excellent. The mean difference in Cobb angles between supine lumbar PA DXA images and upright AP lumbar radiographs was 2.8° in all subjects and 5.8° in those with scoliosis. Conclusions Lumbar spine rotation does not significantly affect BMD and BMC within 15° and 10° of axial and sagittal plane rotation, respectively, and minimally affects Cobb angle measurement. Spine alignment in the coronal plane can be reliably assessed using lumbar PA DXA images.
- 23 February 2021
- Published by Springer Nature in Archives of Osteoporosis
- Vol. 16 (1) , 1-12
Opportunistic use of dual-energy X-ray absorptiometry to evaluate lumbar scoliosis
Summary Low bone mineral density is associated with spinal deformity. Dual-energy X-ray absorptiometry (DXA), a modality that assesses bone density, portends a theoretical means to also assess spinal deformity. We found that DXA can reliably assess spine alignment. DXA may permit surveillance of spine alignment, i.e., scoliosis in the clinical setting. Purpose Osteoporosis and scoliosis are interrelated disease processes. Dual-energy X-ray absorptiometry (DXA), used to assess bone density, can also be used to evaluate spinal deformity since it captures a posteroanterior (PA) image of the lumbar spine. We assessed the use of DXA to evaluate lumbar spine alignment. Methods A lumbar spine DXA phantom was used to assess the effects of axial and sagittal plane rotation on lumbar bone mineral content (BMC), density (BMD), and L1–L4 Cobb angle measurements. Using two subject cohorts, intra- and inter-observer reliability and validity of using DXA for L1–L4 Cobb angle measurements in the coronal and sagittal planes were assessed. Results Axial and sagittal plane rotation greater than 15° and 10°, respectively, significantly reduced measured BMD and BMC; there was minimal effect on Cobb angle measurement reliability. In human subjects, excellent intra- and inter-observer reliability was observed using lumbar PA DXA images for Cobb angle measurements. Agreement between Cobb angles derived from lumbar PA DXA images and AP lumbar radiographs ranged from good to excellent. The mean difference in Cobb angles between supine lumbar PA DXA images and upright AP lumbar radiographs was 2.8° in all subjects and 5.8° in those with scoliosis. Conclusions Lumbar spine rotation does not significantly affect BMD and BMC within 15° and 10° of axial and sagittal plane rotation, respectively, and minimally affects Cobb angle measurement. Spine alignment in the coronal plane can be reliably assessed using lumbar PA DXA images.